Company intelligence / Profile preview
Baudax Bio
Malvern, Pennsylvania, United Statesglobaldata.com ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Phase 2
01
Overview
Baudax Bio’s lead product ANJESO® (IV meloxicam) is FDA-approved for moderate to severe pain. The company’s pipeline includes two novel neuromuscular blocking agents—BX1000 in Phase II and BX2000 in Phase I—and a proprietary reversal agent in preclinical development. Recent clinical data show that BX1000 met primary efficacy endpoints with safety comparable to standard-of-care rocuronium. The company has also explored Treg-based cell therapies for autoimmune diseases but the main focus remains acute care pharmaceuticals
- Therapeutic areas
- OtherImmunologyNeurology
- Modalities
- Small molecules (e.g., meloxicam/ANJESO)neuromuscular blocking agents (NMBs)cell therapy (Treg-based therapies)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Licensing agreement with Cornell University for NMB assets; no major pharma partnerships disclosed publicly as of latest filings.
Beyond the preview
Go deeper on Baudax Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Baudax Bio.